Xenon Pharmaceuticals (XENE) Reiterated at Buy by Stifel - MDD/BPD Study Enrollment Paused
Stifel analyst Paul Matteis reiterated a Buy rating and $86.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).The analyst commented, "XENE's ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)